D2B3
Pre-clinical biotechnology company developing a platform to transiently and specifically relax the blood–brain barrier to enable therapeutic delivery to the brain and central nervous system. The platform is described as compatible with multiple drug classes and intended to support development of CNS-targeted therapies.
Industries
biotechnology
Nr. of Employees
small (1-50)
Products
Proprietary blood–brain barrier modulation platform
A platform technology that transiently and specifically relaxes the blood–brain barrier to facilitate therapeutic targeting of the brain and central nervous system.
Proprietary blood–brain barrier modulation platform
A platform technology that transiently and specifically relaxes the blood–brain barrier to facilitate therapeutic targeting of the brain and central nervous system.
Services
Platform integration and collaborative development
Technical collaboration to apply the delivery platform to external drug candidates, including compatibility assessment and development support for CNS delivery.
Platform integration and collaborative development
Technical collaboration to apply the delivery platform to external drug candidates, including compatibility assessment and development support for CNS delivery.
Expertise Areas
- CNS-targeted drug delivery
- Blood–brain barrier modulation
- Preclinical development for neurologic indications
- Platform integration for multiple therapeutic modalities
Key Technologies
- Blood–brain barrier modulation
- CNS-targeted drug delivery platforms
- Preclinical in vivo models and assays
- Platform integration for therapeutic payloads